Santi is a trained pharmacist graduated from Universitas Gadjah Mada, an entrepreneur in community pharmacy, a lecturer and a researcher in the field of pharmacology, cancer biology, genetics and molecular pathology. She combined her scientific expertise with her personal experience as cancer survivor to found PathGen Diagnostik Teknologi, a start-up which focuses on utilising low-cost technology for molecular genotyping to guide the care of cancer (and other diseases) in resource-limited countries like Indonesia.
She obtained a M.Phil (Master of Philosophy) from The John Curtin School of Medical Research at the Australian National University. She is currently finishing her PhD and now a research fellow in Molecular Pathology Group, School of Medicine, University of Nottingham and a lecturer at Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Muhammadiyah Purwokerto.
Together with her supervisor in Nottingham, Professor Mohammad Ilyas, she established an initiative called NICCRAT (Nottingham-Indonesia Collaboration for Clinical Research and Training) to foster partnership in research and capacity building with various institution in Indonesia, including Indonesian Institute of Science (Lembaga Ilmu Pengetahuan Indonesia/LIPI), Stem Cell and Cancer Institute of Kalbe Farma, Tbk and several medical schools such as in Univeristas Gadjah Mada, Universitas Yarsi, and Muhammadiyah University network.
Astrid Unggul Pawestri
Astrid is a law graduate from Universitas Gadjah Mada. She pursued a master degree in supply chain management at Erasmus University of Rotterdam. She is certified legal auditor by ASAHI (Asosiasi Auditor Hukum Indonesia/ Indonesia Association for Legal Auditors) and member of PERADI (Perhimpuan Advokat Indonesia/ Indonesia Advocates Association). She is now working as senior counsel of legal and regulatory compliance at a state owned company which engages in port related business.
Prof. Mohammad Ilyas, FRCPath
Principal, Scientific Advisor
Professor Ilyas is Professor of Pathology at the University of Nottingham. His research encompasses both basic science and translational research. His areas of interest include the molecular pathology of cancer (especially the roles of Wnt signalling, CD24 and TNS4 in tumourigenesis), liquid biopsy testing for cancer surveillance and digital pathology. Together with his former PhD student, Ms. Susanti, he initiated the NICCRAT (Nottingham-Indonesia collaboration for Clinical Research and Training) initiative to promote the partnership between researchers in the UK and Indonesia
He obtained his medical degree from Bristol University. He subsequently trained as a histopathologist with a specialist interest in gastrointestinal pathology. He undertook a PhD investigating the genetic basis of colorectal cancer at Oxford University in Sir Walter Bodmers lab. He continued this work as an MRC (Medical Research Council) Clinician Scientist prior to his appointment as professor at University of Nottingham in 2005.
Dr. Wien Kusharyoto
Dr Wien is a Head of Laboratory of Applied Genetic Engineering and Protein Design, Research Center for Biotechnology – Indonesian Institute of Sciences (LIPI). His expertise includes structural bioinformatics (protein modelling, docking and molecular dynamics simulation), protein engineering (molecular cloning and protein expression in E. coli and P. pastoris protein modification, protein chromatography), and molecular diagnostics (multiplex PCR, nucleic acid lateral flow assay).
He did his graduate and postgraduate study in Germany where He obtained his B.Sc. and M.Sc. (Dipl.-Chem. Certificate) from Technical University Braunschweig and his PhD (Dr. rer. nat. Certificate) from University Stuttgart.
Dr. Ahmad Utomo
Dr. Ahmad is a principal investigator in Stem Cell and Cancer Institute of Kalbe Farma, Tbk and a laboratory consultant in Kalbe Genomics (Kalgen). His works mainly focus on developing and validating cost-effective molecular genetic testing platform in tumour genotyping to support personalized medicine.
He did his PhD in molecular medicine at University of Texas Health Science Center, San Antonio, developing transgenic mice model of human breast cancer by spatial and temporal inactivation of BRCA1 gene using cre-recombinase. He spent about 4 years at Harvard Medical School as senior American Lung Association research fellow at Department of Pathology of Brigham and Womens Hospital, studying the mechanism of inflammatory lung injury in Dr Tanya Mayadas laboratory.
Prof. DR. Dr. Aru W. Sudoyo, Sp.PD, KHOM, FINASIM, FACP
Professor Aru is a leading oncologist in Indonesia and senior staff at Division of Hematology and Medical Oncology, Department of Internal Medicine, Universitas Indonesia. He also currently is the chair of Indonesia Cancer Foundation (Yayasan Kanker Indonesia/YKI) and The Indonesian Society for Oncology. He was among the first to publish the work about the higher frequency of young colorectal cancer (CRC) patients in Indonesia. His recent research involves the study of molecular marker of CRC.
Prof. Ian Tomlinson
Professor Tomlinson is a professor of molecular and population genetics at the University of Edinburgh and currently the Director of Edinburgh Cancer Research Centre (including Cancer Research UK Edinburgh Centre). He was previously Director of the Institute of Cancer and Genomic Sciences at the University of Birmingham, having worked before that at the Cancer Research UK London Research Institute, University of Oxford and the Institute of Cancer Research.
His research interests lie in discovering and functionally characterising cancer driver genes, especially germline variants that predispose to cancer. He also has a longstanding interest in cancer evolution, derived from his PhD project in population genetics, with a specific interest in the relative contributions of selection and mutation to cancer growth.
Dr. Ines I Atmosukarto
Business and Development Advisor
Dr. Ines is a scientist, Chief Executive Officer, and Chief Scientific Officer for Lipotek—a niche start-up company based in Canberra, Australia. Lipotek is a privately held Australian company (ABN 51 098 824 509) with laboratories and offices on the campus of the Australian National University. The company operates primarily as a research and development entity seeking to identify, protect, and commercialize proprietary liposome-based technologies. In addition, Ines also spends part of her time with the Irradiation Immunity Interaction lab at the John Curtin School of Medical Research at the Australian National University. Ines was previously a Research Scientist and Project Leader at the Research Center for Biotechnology of the Indonesian Institute of Sciences (LIPI) since 2001-2006.
Ines holds a PhD in Molecular and Cellular Biology from the University of Adelaide. She is an internationally recognized research scientist with numerous awards to her name, including a 2009 Australian Alumni Award for Research and Innovation, presented by the Australian Embassy in Jakarta for her dedication to finding new treatments for cancer and infectious diseases to save the lives of others. Dr. Ines also became the first Indonesian woman to win a fellowship from UNESCO-L’Oreal For Women In Science in 2004. As a recipient of a UNESCO-L’OREAL Fellowship for young women in science she had the opportunity to conduct research on endophytic microbes at the laboratories of Professor Gary Strobel at MSU, USA. In 2012 Ines was also awarded the Anugerah Iptek Nasional by Presiden Susilo Bambang Yudoyono.
Asep M. Ridwanuloh
Asep is a reseacher at Research Center for Genetic Engineering BRIN. He is a member of the International Association for Study of Lung Cancer. He graduated for Universitas Jenderal Soedirman in Purwokerto majoring chemistry and obtained his masters degree in biotechnology in Institute Pertanian Bogor. He has gained experience in how to synthesize some compounds as a drug candidate to inhibit tumour cells, and in the last seven years he has developed some nucleotide-based methods for cancer detection.
Traheka Erdyas B.
Traheka is a macroeconomist with more than 5 years of experience conducting business analysis, economic forecast, and policy impact evaluation. Currently, he is working as a lecturer in the Department of Economics, Universitas Gadjah Mada. He also worked as a economic consultant for various companies and goverment institutions. His recent project was providing cost benefit analysis for the formation and development of pharmaceutical clusters in Batang, Jawa Tengah. Traheka has a Master in Economics from University of Nottingham and SE in Economics from Universitas Gadjah Mada.
Ima Andari U.
Ima has more than 8 years of experience in planning and managing strategic projects and engagement with stakeholders. She is a master graduate in logistics (International Transport) at Cardiff Business School, United Kingdom and earns BSc of Civil Engineering from Institut Teknologi Bandung. She is currently working as corporate strategic senior analyst at a state owned enterprise in port sectors.
A Project management professional who focuses on port industry. Experienced in developing robust planning and strong project delivery with wide range of projects from operation transformation to building port-related innovation management. He holds bachelor degree in Economics from the University of Indonesia and a master degree from Maritime Economics and Logistics at Erasmus University.
dr. Dewa Adyaksa
Research and Development
Dewa was born in Denpasar, Indonesia, in 1989. He received his medical degree from University of Indonesia in 2012. After working in several of Indonesia’s most remote area in the field of medical service and education, he continued his studies at Anatomical Pathology Department Gadjah Mada University, Yogyakarta – Indonesia. There, he pursuing specialist degree in anatomical pathology and currently working on his thesis in which he applied convolutional neural network on pathology images. His interest is focused on developing practical approach to accelerate digital pathology adaptation. “Alea iacta est”: We are at a point of no return, and we just need to be part of it (digital approach to the disease).
Research and Development
Gilang is young scientist with degree in Pharmacy from Universitas Muhammadiyah Purwokerto. Gilang is one of the researchers who is working primarily in PathGen Diagnostik Teknologi doing the day to day research and development for the company. She obtained her masters degree from Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University. She has vast experience in nanoparticle formulation of medicinal plant active compounds for cancer and anti-inflammatory agents.
Hanifa is a young scientist who obtained masters degree from Universitas Gadjah Mada majoring Biomedical Sciences with the tittle of Best Graduates of Master’s Degree Program. She has experience in molecular biology projects, especially in laboratory experiments. In addition, he has experience in teaching as a tutor at several tutoring institutions in Yogyakarta.
She was awarded research grants from DAMAS Research Funding, Colaboration of Lecture and Student Scheme about Exploration of cellular-molecular effects of Chlorogenic Acid (CGA) on Rat’s Heart Diabetes Mellitus Model and The Development of Nanoparticles Chitosan let-7a-5p and Chlorogenic Acid and Its Effect to Triple-Negative Breast Cancer Cell Line. She also awarded the PKM-PE (Research Funding) in 2015, 2016, 2018 and she was Grand Finalist at the 29th PKM-PIMNAS at Halu Oleo University, Kendari, Southeast Sulawesi, Indonesia from Indonesian Ministry of Education, Research and Technology.
Andi Nurul Annisa
Andi Nurul is a pharmacist who graduated from Universitas Muhammadiyah Purwokerto (UMP). Her activities are being a student at MSc in Social and Administrative Pharmacy Department, Chulalongkorn University and working as executive assistant at PathGen. She is also a pharmacoeconomic-scientist from UMP who got involved in several health economics and outcomes research, including the HPV Vaccine and Leprosy Post-Exposure Prophylaxis (LPEP) programmes.
She has joined as The Indonesian Health Technology Assessment Agencies in 2019 to analyse cost-utilisation of fibrinolytic therapy in Myocardium Infarct with ST Segmen Evaluation along with the Centre of Health Financing and Security, the Indonesian Ministry of Health. With her current activities, She truly wishes expanding her abilities to provide recommendation for policy-decision making in novel drugs, medical devices, and health-related procedures and support value-based care research.